On the other hand, a different analysis from Delveinsight suggests that although Epidyolex is about to continue dominating the market and remaining a key earner for Jazz within the close to foreseeable future, a rising number of viable alternative remedies within the uncommon epilepsies, specifically from bexicaserin and zorevunersen, that are now